AIM ImmunoTech (AIM) director converts Series G preferred into 25,000 shares

Rhea-AI Filing Summary

AIM ImmunoTech Inc. director David I. Chemerow converted preferred stock into common shares. He converted 25 shares of Series G Convertible Preferred Stock into 25,000 shares of common stock through a derivative conversion at no stated cash price. A footnote explains each preferred share is convertible into 1,000 common shares, effectively valuing the conversion at $1.00 per common share. Following the conversion, he directly holds 28,441 shares of AIM ImmunoTech common stock, with no remaining Series G preferred shares reported.

Insights

Equity compensation and insider-transactions analyst

Director converts preferred stock into common shares, increasing direct equity holdings.

Director David I. Chemerow converted 25 shares of Series G Convertible Preferred Stock into 25,000 shares of common stock via a derivative conversion coded "C". The effective conversion rate is 1,000 common shares per preferred share, or $1.00 per common share per the footnote.

After the transaction, he directly holds 28,441 common shares, and the filing shows no remaining Series G preferred position. With no open-market buying or selling reported and a neutral net buy/sell summary, this appears as a structural shift from preferred to common equity rather than a market-timing trade.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CHEMEROW DAVID I.

(Last) (First) (Middle)

C/O AIM IMMUNOTECH INC.,

2117 SW HIGHWAY 484

(Street)

OCALA, FL 34473

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AIM ImmunoTech Inc. [ AIM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/12/2026		C		25,000	A	$0	28,441	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series G Convertible Prefered Stock	(1)	03/12/2026		C			25	03/06/2026	(2)	Common Stock	25,000	$0(1)	0	D

Explanation of Responses:

1. The preferred shares are convertible into common stock at a rate of 1,000 shares of common stock per whole preferred share, effectively $1.00 per share of common stock.

2. None

	/s/ David I Chemerow	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did AIM ImmunoTech (AIM) director David I. Chemerow report?

David I. Chemerow reported a derivative conversion, changing 25 shares of Series G Convertible Preferred Stock into 25,000 shares of AIM ImmunoTech common stock. This was coded as a conversion ("C"), not an open-market purchase or sale.

How many AIM ImmunoTech common shares did the director receive from the preferred stock conversion?

The director received 25,000 shares of common stock from converting 25 shares of Series G Convertible Preferred Stock. The Form 4 also shows he holds 28,441 common shares directly after the transaction is completed.

What is the conversion rate of AIM ImmunoTech’s Series G Convertible Preferred Stock?

The footnote states each preferred share is convertible into 1,000 shares of common stock, effectively valuing the conversion at $1.00 per common share. This rate produced 25,000 common shares from 25 preferred shares in the reported transaction.

Did the AIM ImmunoTech director buy or sell shares on the open market in this Form 4?

No open-market buys or sells were reported. The Form 4 shows a conversion of derivative securities (code "C"), where preferred shares were converted into common shares without a reported market purchase or sale transaction.

What are David I. Chemerow’s AIM ImmunoTech holdings after this Form 4 transaction?

After the conversion, the Form 4 lists 28,441 shares of common stock held directly by David I. Chemerow. It also shows zero Series G Convertible Preferred Stock remaining following the reported transaction.

Does the Form 4 show any remaining derivative securities for the AIM ImmunoTech director?

The derivative summary is empty, and the transaction leaves 0 shares of Series G Convertible Preferred Stock reported. This indicates no remaining Series G preferred position after the 25 preferred shares were fully converted into common stock.